Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

The Lancet

Volumn 344, Issue 8930, 1994, Pages 1105-1110

  Elliott, M J ^a,b   Maini, R N ^a,b   Feldmann, M ^a,b   Kalden, J R ^c   Antoni, C ^c   Smolen, J S ^d   Leeb, B ^d   Breedveld, F C ^e   Macfarlane, J D ^e   Bijl, J A ^f   Woody, J N ^f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d GENERAL HOSPITAL LINZ   (Austria)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SKIN DISEASE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PLACEBOS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0028143211     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(94)90628-9     Document Type: Article

References (26)

1. Clinical managment of rheumatoid arthritis
2. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
3. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumour necrosis factor &agr
4. Anti-tumour necrosis factor ameloriates joint disease in murine collagen-induced arthritis
5. Involvement of endogenous tumour necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice
6. Does TNFα have a pivotal role in the cytokine network in rheumatoid arthritis?
7. TNFα in rheumatoid arthritis and prospects of anti-TNF therapy
8. Treatment of rheumatoid arthritis with chimaeric monoclonal antibodies to tumour necrosis factor &agr
9. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
10. Therapeutic criteria in rheumatoid arthritis
11. Construction and initial characterisation of a mouse-human chimaeric anti-TNF antibody
12. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo
13. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
14. EULAR standing committee for international clinical studies including therapeutic trials (ESCISIT)
15. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis
16. DAB486IL-2 fusion toxin in refractory rheumatoid arthritis
17. Double blind placebo-controlled phase II trial of diphtheria-interleukin-2 fusion toxin (DAB486IL-2) in patients with refractory rheumatoid arthritis (RA)
18. New directions for biological therapy in rheumatoid arthritis
19. Minimal efficacy of a depleting chimaeric anti-CD4 (cM-T412) in treatment of patients with refractory rheumatoid arthritis (RA) receiving concomitant methotrexate (MTX)
20. Evidence that tumour necrosis factor has an important role in antibacterial resistance
21. Mice deficient for the 55kd tumour necrosis factor receptor are resistant to endotoxic shock, yet succumb to L monocytogenes infection
22. Chronic exposure to TNFα in vitro impairs the activation of T cells through the T cell receptor/CD3 complex reversal in vivo by anti-TNFα antibody in patients with rheumatoid arthritis
23. Mechanisms of erythroid suppression in the anemia of chronic disease
24. Chronic exposure to tumour necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice
25. Tumour-necrosis-factor antibody treatment in Crohn's disease